Login     Register  
    Home   |   Search   |   Director's Bio   |   About/Contact Us   |   Disclaimer  
BioEndeavor - Empowering Women  
 Home
 About BioEndeavor
 Engaged Thinking
 Engaged Thinking Blog
 Engaged Innovation Case Studies
 Engaged Thinking Academy
 Resources
 Engaged Innovation Directory
 Capacity Development
Neglected Tropical Diseases 
Non-Communicable Diseases 

Drug Discovery 
Preclinical 
Clinical 
Healthcare 
 Add Organization 


Drug Discovery
The Pediatric Praziquantel ConsortiumGo Back  
Organization URL

Organization:
The Pediatric Praziquantel Consortium

Year Established: 2012

Profile:
The Pediatric Praziquantel Consortium was founded in July 2012. Its ultimate objective is to develop and register a new praziquantel pediatric formulation for the treatment of schistosomiasis in preschool-age children, including infants and toddlers. In this consortium of highly driven partners, Merck, responsible for leading the program, also brings the necessary chemistry and manufacturing expertise, resources, and support related to praziquantel. In addition, it provides the preclinical, clinical and regulatory resources necessary to efficiently and successfully execute the project. Astellas Pharma Inc. contributes by providing its innovative pharmaceutical technologies in the area of drug formulation development and clinical development in children. Swiss TPH brings extensive experience in helminths biological and pharmacological research, epidemiology and clinical research on drug effectiveness and efficiency in endemic regions. The governance is facilitated by TI Pharma, a non-profit organization and independent party with an extensive portfolio of international public-private partnerships in drug research and development, including in the area of neglected diseases. Farmanguinhos, the federal governmental pharmaceutical laboratory of the Fiocruz Foundation in Brazil, brings unique expertise to produce and distribute the new pediatric formulations product in endemic countries. Simcyp, a small UK research-based company, will build and validate a pharmacokinetic model that will allow a better prediction of the appropriate dosage for use in the pediatric clinical trials.

Target Sector:
Drug Discovery

Typology of Knowledge Network:
Public-Private Partnership (PPP)

Knowledge Type / Focus:
Data
Biological Tools
Biological Materials

Participant Type:
Academic
Non-Profit
Government
Private Sector

Objective / Knowledge Governance:
Cooperative Research


2010-2017 BioEndeavor.Net
Privacy and Security Statement Disclaimer Adding Directory Profiles